Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Z Wei

Showing results (471-480 of 475) with videos related to

Pageof 48
Sort By:
You have reached the last page of results.This site can display upto 475 results.
Nature Medicine|July 13, 2026
An anti-PMEL antibody-drug conjugate with a G<sub>q/1</sub><sub>1</sub> inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trialMatteo S Carlino, Ellen Kapiteijn, Sophie Piperno-Neumann, et al.
NPJ Precision Oncology|March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trialA S Mansfield, Z Wei, R Mehra, et al.
Neurosurgery|December 5, 2025
Outcomes of Repeat Stereotactic Radiosurgery for Recurrent or Progressive Sporadic Vestibular Schwannoma: A Multicenter International StudySalem M Tos, Mariam Ishaque, Georgios Mantziaris, et al.
Nature Ecology & Evolution|May 19, 2025
Aridity modulates grassland biomass responses to combined drought and nutrient additionV F Bondaruk, C Xu, P Wilfahrt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2023
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III studyX Q Yan, M J Ye, Q Zou, et al.
Pageof 48

Showing results (471-480 of 475) with videos related to

Sort By:
Pageof 48
You have reached the last page of results.This site can display upto 475 results.
Nature Medicine|July 13, 2026
An anti-PMEL antibody-drug conjugate with a G<sub>q/1</sub><sub>1</sub> inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trialMatteo S Carlino, Ellen Kapiteijn, Sophie Piperno-Neumann, et al.
NPJ Precision Oncology|March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trialA S Mansfield, Z Wei, R Mehra, et al.
Neurosurgery|December 5, 2025
Outcomes of Repeat Stereotactic Radiosurgery for Recurrent or Progressive Sporadic Vestibular Schwannoma: A Multicenter International StudySalem M Tos, Mariam Ishaque, Georgios Mantziaris, et al.
Nature Ecology & Evolution|May 19, 2025
Aridity modulates grassland biomass responses to combined drought and nutrient additionV F Bondaruk, C Xu, P Wilfahrt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2023
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III studyX Q Yan, M J Ye, Q Zou, et al.
Pageof 48